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A number of studies have shown that CD8+ T cells mediate protective anti-malaria immunity in a mouse
model. However, whether human CD8+ T cells play a role in protection against malaria remains
unknown. We recently established human immune system (HIS) mice harboring functional human
CD8+ T cells (HIS-CD8 mice) by transduction with HLA-A⁄0201 and certain human cytokines using
recombinant adeno-associated virus-based gene transfer technologies. These HIS-CD8 mice mount a
potent, antigen-specific HLA-A⁄0201-restricted human CD8+ T-cell response upon immunization with
a recombinant adenovirus expressing a human malaria antigen, the Plasmodium falciparum circumsporo-
zoite protein (PfCSP), termed AdPfCSP. In the present study, we challenged AdPfCSP-immunized HIS-CD8
mice with transgenic Plasmodium berghei sporozoites expressing full-length PfCSP and found that
AdPfCSP-immunized (but not naïve) mice were protected against subsequent malaria challenge. The level
of the HLA-A⁄0201-restricted, PfCSP-specific human CD8+ T-cell response was closely correlated with the
level of malaria protection. Furthermore, depletion of human CD8+ T cells from AdPfCSP-immunized HIS-
CD8mice almost completely abolished the anti-malaria immune response. Taken together, our data show
that human CD8+ T cells mediate protective anti-malaria immunity in vivo.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction against malaria infection not only in experimental animals but alsoMalaria is a mosquito-borne infectious disease caused by para-
sitic protozoans of the genus Plasmodium. Although medications
and mosquito control efforts have limited the disease, malaria is
still pandemic, with 198 million cases occurring in 2013, resulting
in 584,000 fatalities [1]. These data underscore the need for new
methods to control this disease, including more effective vaccines.
Most vaccine efforts are directed against the pre-erythrocytic
stages [sporozoites (Spz) and liver stages], and blood stages [2].
The finding that vaccination with radiation-attenuated sporozoites
(IrSpz) can induce complete protection (i.e., sterile immunity)in man [3–7] demonstrated the feasibility of effective vaccination
against this disease. A number of mouse studies to date using Plas-
modium yoelii and Plasmodium berghei parasites for challenge have
shown that protective immunity against pre-erythrocytic stages is
mediated in part by T cells, particularly CD8+ T cells. Firstly, the
major role for CD8+ T cells was shown by studies in which
in vivo depletion of CD8+ T cells abrogated Spz-induced protective
immunity in mice [8,9]. Secondly, the adoptive transfer of CD8+ T-
cell clones specific for the immunodominant CD8+ T-cell epitope of
the P. berghei or P. yoelii circumsporozoite protein (CSP), a major
Spz antigen, confers protection against Spz challenge in naïve mice
[10–12]. Using transgenic mice expressing a T-cell receptor (TCR),
based on the TCR sequence of CD8+ T cells recognizing a CD8+ T-
cell epitope present in P. yoelii CSP (PyCSP), transgenic CD8+ T cells
were shown to mediate protection against malaria [13]. Finally, a
single immunizing dose of a recombinant adenovirus expressing
the PyCSP, AdPyCSP, has been shown to induce a potent protective
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cells [14].
Beyond mouse model, Hoffman’s group has recently shown that
intravenous (IV) immunization of IrSpz of Plasmodium falciparum,
PfSPZ vaccine, is very effective in inducing a high frequency of
malaria-specific CD8+ T cells in the liver of nonhuman primates
[15]. More recently the same group showed that immunization
of multiple doses of their IrPfSPZ vaccine by IV induced a high level
of PfSPZ-specific T-cell responses, including that of CD8+ T cells,
and conferred protection in six out of six (100%) human vaccinees
against malaria challenge [16]. Another recent study has shown
that the administration of live P. falciparum Spz by bites of infected
mosquitoes, followed by chloroquine treatment induced signifi-
cant malaria-specific pluripotent effector memory T-cell responses
in vaccinated volunteers and protected all of them (10 out of 10)
upon malaria challenge [17]. With regards to human malaria vac-
cines based on viral vectors, a small number have entered human
clinical trials in recent years. In a phase I clinical trial, 15 volun-
teers were primed with plasmid DNA encoding P. falciparum CSP
(PfCSP) and apical membrane antigen-1 and then boosted with
human adenovirus serotype 5 (Ad5) expressing the same antigens.
This DNA priming/adenovirus boost immunization regimen
induced sterile protection in four (27%) vaccinated subjects [18].
In a phase IIa clinical trial, vaccination using a priming-boost reg-
imen based on chimpanzee adenovirus and modified Ankara vac-
cinia virus, both expressing P. falciparum thrombospondin
adhesive protein fused to multiple epitopes derived from several
malaria antigens, induced sterile protection in 21% (3 out of 14)
of subjects and delayed patency in 36% (5 out of 14) of subjects
[19]. Although the degree of protection in these trials was modest,
both trials exhibited a trend toward a higher-level vaccine-induced
CD8+ T-cell response in protected individuals [18,19]. Finally, it has
been shown that the PfCSP also contains CD8+ T cell epitopes
[20,21] and can elicit a potent CD8+ T-cell response in humans
upon immunization with various human malaria vaccines, includ-
ing PfSPZ and AdPfCSP [22–26].
In a previous study, we established a human immune system
(HIS) mouse model by transducing genes encoding human HLA-
A⁄0201 and human cytokines using a recombinant adeno-
associated virus serotype 9 (AAV9) vector [27]. These mice express
functional HLA-A⁄0201-restricted human CD8+ T cells, and were
therefore designated HIS-CD8 mice. In the present study, the role
of vaccine-induced human CD8+ T cells in mediating protective
immunity against malaria was investigated in HIS-CD8 mice.
2. Materials and methods
2.1. Ethics statement
All animal experiments were carried out in strict accordance
with the Policy on Humane Care and Use of Laboratory Animals
of the United States Public Health Service. The protocol was
approved by the Institutional Animal Care and Use Committee
(IACUC) at The Rockefeller University. Mice were euthanized using
CO2, and every effort was made to minimize suffering. Human fetal
liver samples were obtained via a non-profit partner (Advanced
Bioscience Resources, Alameda, CA). As no information was
obtained that would identify the subjects from whom the samples
were derived, Institutional Review Board approval for their use was
not required, as previously described [27].
2.2. Mice
NOD.Cgtm1Unc Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice exhibiting fea-
tures of both severe combined immunodeficiency mutations and
interleukin (IL)-2 receptor gamma-chain deficiency were pur-chased from Jackson Laboratories (Bar Harbor, ME) and maintained
under specific pathogen-free conditions in the animal facilities at
The Rockefeller University Comparative Bioscience Center.
2.3. Generation of HIS-CD8 mice
Recombinant AAV9 (rAAV9) vectors encoding human IL-3, IL-
15, GM-CSF, and HLA-A⁄0201 were constructed as previously
described [27]. Four-week-old NSG mice were transduced with
rAAV9 encoding HLA-A⁄0201 by intrathoracic (IT) injection and
with rAAV9 encoding HLA-A⁄0201 and AAV9 encoding human IL-
3, IL-15, and GM-CSF, by intravenous (IV) injection, as previously
described [27]. Two weeks later, mice were subjected to 150-Gy
total body sub-lethal irradiation for myeloablation, and several
hours later, each transduced, irradiated mouse was engrafted
intravenously with 1  105 HLA-A⁄0201+ matched, CD34+ human
hematopoietic stem cells (HSCs). CD34+ HSCs among lymphocytes
derived from HLA-A⁄0201+ fetal liver samples were isolated using
a Human CD34 Positive Selection kit (STEMCELL TECHNOLOGIES
Inc. Vancouver, BC, Canada) [28]. At 14 weeks after HSC engraft-
ment, the reconstitution status of human CD45+ cells in the blood
of HIS-CD8 mice was determined by flow cytometric analysis, as
previously described [27].
2.4. Recombinant adenovirus and transgenic parasites
A recombinant adenovirus serotype 5 (Ad5) expressing a green
fluorescent protein (GFP) alone in its transgene, AdGFP, was previ-
ously constructed [29]. A recombinant Ad5 expressing P. falciparum
CSP (AdPfCSP) was also previously constructed as described [29].
Briefly, a gene encoding a full length PfCSP was codon-optimized
and synthesized, followed by being inserted into pShuttle-CMV,
which was then used to make the recombinant AdPfCSP. HIS-CD8
mice were immunized with 5  1010 AdPfCSP virus particles
[27,29]. A transgenic P. berghei sporozoite expressing full-length
P. falciparum CSP (FLPfCSP/Pb sporozoite) was generated as previ-
ously described [30,31] and maintained at the Insectary Core Facil-
ity of New York University.
2.5. Intra-cellular cytokine staining (ICS)
Spleens were harvested from HIS-CD8 mice 10 days after vacci-
nation with AdPfCS or AdGFP or from naïve HIS-CD8 mice. After
isolation of lymphocytes, the cells were counted and used for ICS
upon stimulation with synthetic peptides corresponding to the
A2-restricted CD8+ T-cell epitopes of the PfCSP (YLNKIQNSL,
KLRKPKHKKL and SLKKNSRSL) [20,21]. Briefly, Lymphocytes were
stimulated for 4–6 h using a pool of the synthetic peptides listed
above or none (as a negative control) in the presence of brefeldin
at 37 C with 5% CO2. ICS assays were performed as previously
described [16]. Briefly, after blocking with the anti-mouse CD16/
CD32 antibody, lymphocytes were stained for surface markers
with antibodies against CD45, CD3, and CD8. Next, lymphocytes
were permeabilized with perm/wash solution (BD Biosciences,
San Jose, CA), stained with the FITC-labeled anti-human IFN-c anti-
body, fixed with 1% paraformaldehyde, and analyzed using a BD
LSR II (BD Biosciences).
2.6. Staining with HLA-A⁄0201 tetramer loaded with YLNKIQNSL
peptide
An Allophyocyanin-labeled human HLA-A⁄0201 tetramer
loaded with the peptide YLNKIQNSL, corresponding to the PfCSP
CD8+ T-cell epitope [20,21], was provided by the NIH Tetramer
Core Facility. HIS-CD8 mice were immunized with AdPfCSP, and
10 days later, the mice were challenged with 2  104 live
X. Li et al. / Vaccine 34 (2016) 4501–4506 4503FLPfCSP/Pb sporozoites by IV injection. After 42 h, the spleens were
harvested, and splenocytes were stained with APC-labeled human
HLA-A⁄0201 tetramer loaded with YLNKIQNSL and PE-labeled
anti-human CD8 antibody (BioLegend, San Diego, CA). The percent-
age of HLA-A⁄0201-restricted, PfCSP-specific CD8+ T cells among
the total human CD8+ T-cell population was determined using a
BD LSR II flow cytometer (Franklin Lakes, NJ).
2.7. Sporozoite challenge and assessment of parasite burden in the
liver
FL-PfCSP/Pb sporozoites were obtained from salivary glands
dissected from infected Anopheles stephensi mosquitoes 2 weeks
after an infective blood meal. Sporozoite challenge experiments
were carried out as described previously [30,31]. Briefly, immu-
nized mice were injected with 2  104 live sporozoites via the tail
vain, and 42 h after the challenge, the parasite burden in the liver
was determined by measuring parasite-specific ribosomal RNA
using a 7300 Real-Time PCR system (Applied Biosystems, Wal-
tham, MA). Parasite burden was defined as the ratio of the absolute
copy number of parasite ribosomal RNA to that of mouse GAPDH
mRNA, and the percentage was calculated in relation to the para-
site burden in naïve mice.
2.8. In vivo depletion of human CD8+ T cells
For the depletion of human CD8+ T cells, 0.1 mg of the rhesus
IgG1 anti-human CD8 mAb MT807R1 [32], as well as rhesus
recombinant IgG1 antibody, as an isotype control (both purchased
from the NIH Nonhuman Primate Reagent Resource, Boston, MA),
were administered to each HIS-CD8 mouse by intraperitoneal (IP)
injection at 5 days and 2 days before sporozoite challenge. The
spleen was harvested from each mouse 42 h after the challenge,
and splenocytes were stained with the following antibodies (all
purchased from BioLegend): Pacific Blue-labeled anti-human
CD45, PerCP/Cy5.5-labeled anti-mouse CD45, PE-Cy7-labeled
anti-human CD3, Alexa Fluor 700-labeled anti-human CD8, APC-
Cy7-labeled anti-human CD4, and PE-labeled anti-human CD19.
The degree of human CD8+ T-cell depletion was assessed using a
BD LSR II.
2.9. Human IgM ELISA
The serum level of human IgMwas determined by ELISA (Bethyl
Laboratories, Montgomery, TX), as we previously performed [33].
2.10. Statistical analysis
All of the statistical analyses were done using GraphPad Prism
(ver. 4.03) (GraphPad Software, Inc.). Bars in each figure represent
geometric means. In all experiments, the values were log-
transformed and then one-way ANOVA followed by a Dunnett’s
test was employed to determine the differences between the
groups. For a correlation analysis, linear regression analysis was
applied to % of PfCSP-specific CD8+ T cells among the total human
CD8+ T-cell population and % of relative parasite burden in liver, as
100% being the parasite burden in naïve and challenged mice.
3. Results
3.1. Establishment of HIS-CD8 mice
As described previously [27], we reconstituted functional
human CD8+ T cells by delivering genes encoding HLA-A⁄0201
and then selected human cytokines using rAAV9 as a vector.Briefly, NSG mice were administered rAAV9 encoding HLA-
A⁄0201 by both IV and IT injection plus an IV injection of a cocktail
of rAAV9 vectors encoding human IL-3, IL-15, and GM-CSF, fol-
lowed by engraftment of HLA-A⁄0201+ CD34+ HSCs. Determina-
tion of the phenotypes of peripheral blood mononuclear cells
(PBMCs) by flow cytometric analysis after 14 weeks revealed that
human CD45+ cells constituted more than 90% of the total PBMC
population in the HIS mice (Fig. 1B). These HIS-CD8 mice can
mount human IgM in their sera (data not shown).
3.2. Correlation of the level of the PfCSP-specific CD8+ T-cell response
induced in HIS-CD8 mice and the level of malaria protection
A group of three HIS-CD8 mice were first immunized with
5  1010 virus particles of AdPfCSP or AdGFP, as a control, by intra-
muscular (IM) injection (Fig. 1A). IM route was chosen because of
the practicality and also the safety issue. Ten days later, spleens
were removed from a group of immunized HIS-CD8 mice, and
ICS was performed in the presence or absence of a pool of PfCSP-
derived CD8+ T-cell epitopes to determine the percentage of
PfCSP-specific human CD8+ T cells secreting human IFN-c. We
found that AdPfCSP-immunized, but not AdGFP-immunized, HIS-
CD8 mice were able to induce a significant level of PfCSP-specific
human CD8+ T-cell response (Fig. 1C). In the next experiments,
another group of five AdPfCSP-immunized, as well as five naïve
HIS-CD8 mice, were challenged IV with 2  104 live FLPfCSP/Pb
sporozoites 10 days after immunization (Fig. 2A). The level of the
PfCSP-specific human CD8+ T-cell response induced in the spleen
was determined 42 h after the sporozoite challenge by flow cyto-
metric analysis using an HLA-A⁄0201 tetramer loaded with YLN-
KIQNSL, a peptide representing the HLA-A⁄0201-restricted
human CD8+ T-cell epitope present in PfCSP [20,21]. We found that
a PfCSP-specific, HLA-A⁄0201-restricted human CD8+ T-cell
response was generated only after vaccination with AdPfCSP fol-
lowed by challenge with live FLPfCSP/Pb sporozoites and not after
challenge with FLPfCSP/Pb sporozoites alone (Fig. 2B). When we
determined the parasite load in the liver of both AdPfCSP-
immunized and naïve HIS-CD8 mice at 42 h after FLPfCSP/Pb
sporozoite challenge, we found that the parasite load was reduced
by 91% in AdPfCSP-immunized mice compared with the naïve con-
trol group, indicating that immunization with AdPfCSP conferred
protection against malaria (Fig. 2C). Importantly, a significant cor-
relation (p = 0.006) was observed between the level of the PfCSP-
specific human CD8+ T-cell response and the level of malaria pro-
tection (Fig. 2D).
3.3. Abolishment of malaria protection observed in AdPfCSP-
immunized HIS-CD8 mice by in vivo depletion of human CD8+ T cells
In order to determine the role of human CD8+ T cells in mediat-
ing the protective anti-malaria immune response observed in HIS-
CD8 mice, a group of AdPfCSP-immunized HIS-CD8 mice received
two IP injections of the monoclonal anti-human CD8+ T-cell anti-
body, MT807R1 (0.1 mg/mouse/injection) [32], 5 days and 8 days
after AdPfCSP immunization (Fig. 3A). Rhesus IgG1 antibodies were
administered to another group of AdPfCSP-immunized HIS-CD8
mice, as an isotype control. At 10 days after AdPfCSP immuniza-
tion, naïve HIS-CD8 mice, AdPfCSP-immunized HIS-CD8 mice,
and AdPfCSP-immunized, anti-human CD8+ antibody-treated
HIS-CD8 mice were challenged with live FLPfCSP/Pb sporozoites.
The spleen and liver were harvested from each mouse 42 h later
to determine the percentage of human CD8+ T cells and the para-
site burden, respectively (Fig. 2A). Flow cytometric analysis con-
firmed that administration of anti-human CD8+ antibody, but not
the isotype control antibody, resulted in 100% depletion of human
CD8+ T cells in the spleen of HIS-CD8 mice (Fig. 3B). Most impor-
Fig. 1. AdPfCSP vaccination induced PfCSP-specific human CD8+ T cells secreting human IFN-c in HIS-CD8 mice. (A) A group of three HIS-CD8 mice were immunized by IM
injection with AdPfCSP or AdGFP at 1010 virus particles/mouse, and 10 days later, spleens were harvested from the both groups and lymphocytes isolated. (B) Prior to
immunization, blood was collected from HIS-CD8 mice, and the percentage of human CD45+ cells in the blood was determined by a flow cytometric analysis. (C) Using
lymphocytes isolated from the spleen, ICS was performed to assess the percentage of PfCSP-specific human CD8+ T cells secreting human IFN-c among total CD8+ T cells by a
flow cytometric analysis.
Fig. 2. PfCSP-specific CD8+ T-cell response and protective anti-malaria response induced in HIS-CD8 mice. (A) Five HIS-CD8 mice were immunized by i.m. injection with
AdPfCSP at 5  1010 virus particles/mouse. After 10 days, the AdPfCSP-immunized mice, as well as five naïve HIS-CD8 mice, were challenged by i.v. injection with 2  104 live
FLPfCSP/Pb sporozoites. (B) After 42 h, both groups of HIS-CD8 mice were sacrificed, and the percentage of HLA-A2-restricted, PfCSP-specific CD8+ T cells among total CD8+ T
cells in the spleen was determined using HLA-A2 tetramer staining and flow cytometric analysis. (C) The parasite load in the liver was determined by qRT-PCR analysis. (D)
The correlation between the percentage of PfCSP-specific CD8+ T cells and the relative parasite load in the liver was assessed using Prim GraphPad 5.0 software.
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almost completely abolished the inhibition of live-stage malaria
parasites observed in HIS-CD8 mice upon AdPfCSP immunization
(Fig. 3C). These results indicate that human CD8+ T cells mediate
the protective anti-malaria immune response induced in HIS mice
by the human malaria vaccine examined in this study.4. Discussion
The role of CD8+ T cells in protective immunity against malaria,
particularly immunity against the pre-erythrocytic stages of theparasite, has been examined in a number of mouse studies using
rodent malaria parasites, such as P. yoelii or P. berghei, as a chal-
lenge model [8–13]. As described in the Introduction, a small num-
ber of candidate human malaria vaccines based on viral vectors
have entered human clinical trials in recent years. Ad5 vectors
expressing PfCS and PfAMA-1 were shown to elicit a significant
level of CD8+ T-cell response, but a modest degree of protection,
with a correlation reported between the level of the CD8+ T-cell
response and the degree of protection [22,23]. The reason why only
the modest degree of the protective immunity could be induced by
Ad5 vector-based vaccines was, in part, due to the pre-existing
anti-Ad5 immunity present in the vaccinees. Nevertheless, this
Fig. 3. In vivo depletion of human CD8+ T cells abolished protective anti-malaria immunity induced in AdPfCSP-immunized HIS-CD8 mice. (A) Six HIS-CD8 mice were
immunized by IM injection with AdPfCSP at 5  1010 virus particles/mouse. A group of three AdPfCSP-immunized HIS-CD8mice received two 0.1 mg/mouse doses of anti-CD8
mAb, MT807R1, or rhesus recombinant IgG1, as an isotype control, by IP injection on days 5 and 8 post-AdPfCSP immunization. After 10 days, three AdPfCSP-immunized HIS-
CD8 mice, three AdPfCSP-immunized/human CD8+ T-cell depleted HIS-CD8 mice, and three naïve HIS-CD8 mice were challenged by IV injection with 2  104 live FLPfCSP/Pb
sporozoites. (B) After 42 h, both groups of HIS-CD8 mice were sacrificed, and the percentages of human CD8+ and CD4+ T cells among the total human T-cell population were
determined by flow cytometric analysis. (C) The parasite load in the liver was determined by qRT-PCR.
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immune response induced by malaria vaccines. However, as it is
impossible to deplete CD8+ T cells in human vaccine recipients,
to date, no conclusive evidence confirming a protective role for
human CD8+ T cells against malaria has been published.
We recently established a HIS-CD8 mouse model in which
AdPfCSP immunization induces an HLA-A⁄0201-restricted, PfCSP-
specific human cytotoxic CD8+ T-cell response [27]. In the current
study, therefore, we sought to determine the role human CD8+ T
cells play in the protective anti-malaria immune response using
HIS-CD8 mice. We have to note that the number of mice used
per group is limited due to the difficulty of expanding HIS-CD8
mice that can possess a high percentage of human lymphocytes
in their blood. The difficulty includes the breeding of NSG mice,
availability of HLA-A⁄0201 matched HSCs, and a long duration
(>15 weeks) after HSCs engraftment for human lymphocytes,
including human CD8+ T cells, to fully develop and expand in
HIS-CD8 mice. Nevertheless, we found that AdPfCSP immunization
was able to induce a significant level of both PfCSP-specific human
CD8+ T-cell response and protective immune response against
challenge with transgenic P. berghei sporozoites expressing full-
length PfCSP. The level of malaria protection was positively corre-
lated with the level of the PfCSP-specific CD8+ T-cell response. Fur-
thermore, depletion of human CD8+ T cells in AdPfCSP-immunizedHIS-CD8 mice almost completely abolished the malaria protection,
thus indicating that human CD8+ T cells mediate protective immu-
nity against malaria, most likely against the liver stages of the
parasite.
In our previous studies, we showed that hepatocytes in HIS-CD8
mice express HLA-A⁄0201 following delivery of the gene via AAV9
and that PfCSP-specific human CD8+ T cells induced by AdPfCSP
immunization recognize HLA-A⁄0201+ hepatocytes presenting a
peptide corresponding to the CD8+ T-cell epitope of PfCSP [27].
In addition, because they were transduced with only the HLA-
A⁄0201 gene, the HIS-CD8 mice can harbor functional human
CD8+ T cells but not functional human CD4+ T or B cells [27]. Taken
together, our results suggest that HLA-A⁄0201-restricted human
CD8+ T cells almost solely mediate the protective anti-malaria
immune response, with no contribution by humoral or CD4+ T-
cell responses. Thus, our data highlight the importance of design-
ing human malaria vaccines that elicit a protective CD8+ T-cell
response.
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